| |
| Issue |
Title |
| |
| No 20 (2021) |
Efficacy of lorlatinib in the treatment of ALK-positive non-small cell lung cancer patients with progression on crizotinib: personal experience |
Abstract
PDF (Rus)
|
|
K. K. Laktionov, E. V. Reutova, S. Yu. Kruteleva, E. Yu. Antonova |
| |
| No 20 (2021) |
Role of Post-Neoadjuvant therapy with trastuzumab emtansine in HER2-positive breast cancer |
Abstract
PDF (Rus)
|
|
E. V. Lubennikova, Ya. V. Vishnevskaya |
| |
| No 20 (2021) |
Target therapy of luminal HER2-negative advanced breast cancer with PIK3CA mutation: combination of alpelisib plus fulvestrant in real clinical practice |
Abstract
PDF (Rus)
|
|
D. A. Filonenko, T. M. Ibragimova, N. I. Polshina, A. V. Belogurova, E. I. Khatkova, E. A. Arutiunian, E. I. Volkova, L. G. Zhukova |
| |
| No 20 (2021) |
Optimal solutions in the third line therapy for refractory metastatic colorectal cancer. CORRECTness and CONCURency |
Abstract
PDF (Rus)
|
|
R. T. Ayupov, A. A. Izmailov, K. V. Menshikov, A. V. Sultanbaev, A. F. Nasretdinov, R. R. Rakhimov, Sh. I. Musin, N. I. Sultanbaeva |
| |
| No 20 (2021) |
Molecular features evaluation of metastatic foci as the basis for metastatic breast cancer treatment personalization. Is there a place of CDK4/6-inhibitors in late-line therapy after chemotherapeutic regimens? |
Abstract
PDF (Rus)
|
|
A. I. Stukan, A. Y. Goryainova, E. V. Lymar, S. V. Sharov, V. V. Antipova |
| |
| No 20 (2021) |
Role of pre-metastatic niche in organ specificity of breast cancer metastasis. Influence on metastatic potential as a basis for CDK4/6-inhibition efficacy in early therapy of disseminated hormone-receptor-positive disease |
Abstract
PDF (Rus)
|
|
A. I. Stukan, A. Yu. Goryainova, E. V. Lymar, S. V. Sharov, D. V. Andreev, V. V. Antipova |
| |
| No 20 (2021) |
Eribulin-trastuzumab combination in HER2-positive metastatic breast cancer: updated results from a Russian observational study |
Abstract
PDF (Rus)
|
|
E. I. Kovalenko, E. V. Artamonova, L. V. Bolotina, L. A. Zhiliaeva, D. M. Ponomarenko, E. V. Karabina, G. Z. Mukhametshina, A. I. Khasanova, E. Yu. Ratner, A. R. Safarova, A. G. Manikhas, N. O. Popova, I. V. Evstigneeva, L. Yu. Vladimirova, L. V. Kramskaya, T. V. Karandeeva, I. R. Suslova, O. V. Romanchuk, V. E. Shikina, A. Yu. Povyshev, M. A. Osipov, E. M. Cherniakova, A. S. Dergunov, M. V. Volkonskiy, I. S. Chernov, I. E. Shumskaya, M. M. Fael, V. I. Garifullina, I. E. Gudkova |
| |
| No 4S (2021) |
Current approaches to therapy of ALK-positive non-small cell lung cancer |
Abstract
PDF (Rus)
|
|
К. К. Laktionov, S Yu. Kruteleva, Е. V. Reutova |
| |
| No 4S (2021) |
Analysis of the clinical efficacy of the cyclin- dependent kinase inhibitor 4/6 Abemaciclib on the clinical case of a male with hormonereceptor- positive breast cancer |
Abstract
PDF (Rus)
|
|
А. Y. Goryainova, А. I. Stukan, Е. V. Lymar, S. V. Sharov, R. A. Murashko, D. V. Andreev |
| |
| No 20 (2020) |
Olaparib in the metastatic HER2-negative breast cancer setting |
Abstract
PDF (Rus)
|
|
L. G. Zhukova, E. I. Khatkova, I. P. Ganshina, I. V. Kolyadina, E. V. Lubennikova |
| |
| No 20 (2020) |
Efficiency and tolerability of abemaciclib in elderly patients |
Abstract
PDF (Rus)
|
|
E. I. Kovalenko, M. V. Khoroshilov, E. V. Artamonova |
| |
| No 20 (2020) |
Inhibitors of cyclin-dependent kinases 4/6 for breast cancer patients with different somatic mutations of the PIK3CA gene |
Abstract
PDF (Rus)
|
|
A. F. Nasretdinov, N. I. Sultanbaeva, Sh. I. Musin, O. N. Lipatov, A. A. Izmailov, R. T. Ayupov, K. V. Menshikov, A. V. Pushkarev, A. V. Sultanbaev |
| |
| No 9 (2020) |
Abemaciclib as an original inhibitor of cyclin-dependent kinase for the treatment of luminal HER2-negative disseminated breast cancer |
Abstract
PDF (Rus)
|
|
N. S. Besova |
| |
| No 9 (2020) |
Clinical aspects of the use of ribociclib |
Abstract
PDF (Rus)
|
|
A. A. Markovich, M. V. Kalugin, O. О. Gordeeva, M. Zh. Yakoobova |
| |
| No 9 (2020) |
PARP inhibitors in the treatment of metastatic breast cancer patients with germline BRCA1/2 mutations. Experience of treatment with talazoparib in clinical practice |
Abstract
PDF (Rus)
|
|
M. A. Frolova, E. V. Glazkova, M. B. Stenina |
| |
| No 19 (2019) |
Postneoadjuvant therapy: a new approach to the treatment of HER2-positive breast cancer (KATHERINE study results) |
Abstract
PDF (Rus)
|
|
L. G. Zhukova, S. A. Smolin |
| |
| No 19 (2019) |
Rational approach to the treatment of EGFR-positive lung cancer |
Abstract
PDF (Rus)
|
|
E. V. Reutova, K. K. Laktionov, D. I. Yudin, M. S. Ardzinba |
| |
| No 19 (2019) |
Second-line treatment of hepatocellular carcinoma: from theory to practical issues |
Abstract
PDF (Rus)
|
|
V. V. Breder, K. K. Laktionov |
| |
| No 19 (2019) |
Treatment tactics of non-small-cell lung cancer with erlotinib: literature review and description of a clinical case |
Abstract
PDF (Rus)
|
|
E. I. Borisova, S. L. Gutorov, M. E. Abramov |
| |
| No 10 (2019) |
Cyclin-dependent kinase inhibitors: efficacy and safety |
Abstract
PDF (Rus)
|
|
I. B. Kononenko, A. V. Snegovoi, V. Yu. Selchuk |
| |
| No 10 (2019) |
Role of palbociclib in the treatment of hormone receptor-positive HER2-negative metastatic breast cancer. Generalizing results of randomized trials and real clinical practice |
Abstract
PDF (Rus)
|
|
L. G. Zhukova, E. I. Khatkova, P. S. Feoklistova, K. S. Grechukhina, S. A. Smolin, E. A. Arutyunyan, E. M. Kolyago |
| |
| No 10 (2019) |
Erlotinib in combined therapy of common lung adenocarcinoma in the presence of EGFR gene mutation |
Abstract
PDF (Rus)
|
|
S. V. Orlov, A. M. Lozhkina, S. V. Odintsova, M. A. Sviridenko, A. O. Cheremnykh, M. A. Urtenova, E. A. Filippova |
| |
| No 10 (2019) |
Ribociclib for the treatment of hormone-positive HER2-negative breast cancer |
Abstract
PDF (Rus)
|
|
I. P. Ganshina, D. A. Filonenko, O. O. Gordeeva, E. V. Lubennikova, I. V. Kolyadina, A. A. Mescheryakov |
| |
| No 10 (2019) |
Second line of therapy for gastrointestinal stromal tumors: is there a choice? |
Abstract
PDF (Rus)
|
|
L. M. Kogonia, A. M. Koroleva |
| |
| No 10 (2019) |
Ceritinib in the treatment of ALK-positive patients with nonsmall-cell lung cancer |
Abstract
PDF (Rus)
|
|
K. K. Laktionov, E. V. Reutova |
| |
| No 19 (2018) |
Modern aspects of antiangiogenic therapy in ovarian cancer |
Abstract
PDF (Rus)
|
|
A. A. Rumyantsev, I. A. Pokataev, S. A. Tyulyandin |
| |
| No 19 (2018) |
Second-line targeted therapy for metastatic colorectal cancer. Possibilities for choices |
Abstract
PDF (Rus)
|
|
L. V. Bolotina, A. D. Kaprin |
| |
| No 19 (2018) |
Ribociclib in the first-line therapy for metastatic hormone-dependent HER2-negative breast cancer in patients with intact ovarian function |
Abstract
PDF (Rus)
|
|
S. F. Menshikova, M. A. Frolova, E. V. Glazkova, M. B. Stenina |
| |
| No 19 (2018) |
Cetuximab in treatment of metastatic colorectal cancer: background and clinical observation |
Abstract
PDF (Rus)
|
|
A. D. Darenskaya, N. V. Dobrova, B. M. Medvedeva |
| |
| No 10 (2018) |
Basal cell cancer treatment. Therapeutic experience with vismodegib therapy |
Abstract
PDF (Rus)
|
|
N. N. Petenko, L. V. Demidov |
| |
| No 10 (2018) |
The use of regorafenib in patients with disseminated gastrointestinal stromal tumours. A review of the literature. A clinical case |
Abstract
PDF (Rus)
|
|
D. A. Filonenko, S. V. Petukhova, E. I. Khatkova, K. A. Vorontsova, E. I. Chichikov, B. M. Medvedeva, L. G. Zhukova |
| |
| No 10 (2018) |
Aflibercept: side effects in focus |
Abstract
PDF (Rus)
|
|
M. Yu. Fedyanin |
| |
| No 10 (2018) |
BCLC-B hepatocellular carcinoma treatment or when should the systemic therapy be started |
Abstract
PDF (Rus)
|
|
V. V. Breder, M. U. Pitkevich, E. R. Virshke, L. A. Kostyakova, I. A. Dzhanyan, K. K. Laktionov |
| |
| No 10 (2018) |
Results of the use of ramucirumab in combination with paclitaxel or ramucirumab monotherapy as the second line treatment in patients with disseminated HER2-negative gastric or cardioesophageal junction adenocarcinoma: experience of N.N. Blokhin russian cancer research center of the ministry of health of Russia |
Abstract
PDF (Rus)
|
|
N. S. Besova, T. A. Titova, E. V. Trusilova, V. A. Gorbunova, A. A. Tryakin, O. O. Gordeeva, A. A. Rumyantsev, R. Yu. Nasyrova, L. G. Zhukova, A. V. Snegovoy, E. V. Artamonova, L. V. Manzyuk, A. A. Fedenko |
| |
| No 14 (2017) |
EXPERIENCE WITH SUBCUTANEOUS TRASTUZUMAB USED IN RUSSIAN FEDERATION |
Abstract
PDF (Rus)
|
|
E. V. Lubennikova, I. P. Ganshina, A. N. Lud, D. V. Komov, I. V. Kolyadina, Y. V. Vishnevskaya, I. K. Vorotnikov, D. L. Stroyakovsky, N. A. Savelov, V. F. Semiglazov, А. G. Manikhas, А. V. Osheychik, T. B. Strelnikova, K. R. Zeynalova, L. G. Zhukova |
| |
| No 14 (2017) |
ПРИОБРЕТЕННАЯ РЕЗИСТЕНТНОСТЬ К ИНГИБИТОРАМ ТИРОЗИНКИНАЗЫ EGFR: ПУТИ ПРЕОДОЛЕНИЯ |
Abstract
PDF (Rus)
|
|
, , , , |
| |
| No 14 (2017) |
AFATINIB IN THE TREATMENT OF METASTATIC AND LOCALLY ADVANCED LUNG ADENOCARCINOMA WITH EGFR MUTATIONS: NEW SIDES STUDIED POSSIBILITIES |
Abstract
PDF (Rus)
|
|
E. V. Karabina, L. N. Lubchenko, M. M. Davydov |
| |
| No 14 (2017) |
CLINICAL CASE OF SUCCESFUL APPLICATION OF KADSYLA APPLICATION IN METASTATIC HER2 POSITIVE BREAST CANCER |
Abstract
PDF (Rus)
|
|
D. D. Sakaeva |
| |
| No 14 (2017) |
REAL-LIFE CLINICAL UTILITY OF RAMUCIRUMAB FOR THE TREATMENT OF PATIENTS WITH DISSEMINATED GASTRIC ADENOCARCINOMA: PRELIMINARY REVIEW OF THE EXPERIENCE OF BLOKHIN RUSSIAN CANCER RESEARCH CENTRE |
Abstract
PDF (Rus)
|
|
N. S. Besova, T. A. Titova, V. A. Gorbunova, O. O. Gordeeva, A. A. Tryakin, A. V. Snegovoy, R. Yu. Nasyrova, A. A. Rumyantsev, E. A. Voroshilova, E. V. Artamonova |
| |
| No 14 (2017) |
REPEATED USE OF BRAF AND MEK INHIBITORS IN METASTATIC MELANOMA PATIENTS AFTER PROFRESSION ON BRAF AND МЕК INHIBITORS. LITERATURE REVIEW AND CLINICAL OBSERVATION |
Abstract
PDF (Rus)
|
|
I. V. Samoylenko, Y. A. Zhulikov, L. V. Demidov |
| |
| No 14 (2017) |
PHARMACOLOGICAL THERAPY OF HEPATOCELLULAR CANCER PRACTICAL ISSUES AND SOLUTIONS |
Abstract
PDF (Rus)
|
|
V. V. Breder, K. K. Laktionov, M. I. Davydov |
| |
| No 6 (2017) |
PARP INHIBITORS IN OVARIAN CANCER: TOXICITY PROFILE |
Abstract
PDF (Rus)
|
|
S. V. KHOKHLOVA, O. A. SHILKINA |
| |
| No 6 (2017) |
NEW STRATEGY FOR DRUG TREATMENT OF LUMINAL HER2-NEGATIVE METASTATIC BREAST CANCER |
Abstract
PDF (Rus)
|
|
E. V. ARTAMONOVA |
| |
| No 6 (2017) |
ALGORITHMS FOR MANAGEMENT OF PATIENTS WITH ADVERSE EVENTS ON THERAPY WITH TYROSINE KINASE INHIBITORS EGFR |
Abstract
PDF (Rus)
|
|
D. D. SAKAEVA |
| |
| No 6 (2017) |
TARGETED THERAPY OF LUNG CANCER WITH THE ROS1 REARRANGEMENT |
Abstract
PDF (Rus)
|
|
K. K. LAKTIONOV, E. V. REUTOVA, M. S. ARDZINBA, N. A. MESCHERYAKOVA |
| |
| 1 - 45 of 45 Items |
|
